Valerio Therapeutics

Kalender

2023-09-28	Kvartalsrapport 2023-Q2
2023-06-06	Extra Bolagsstämma
2023-06-06	Årsstämma 2023
2023-04-24	Bokslutskommuniké 2022
2023-02-06	Extra Bolagsstämma
2022-09-13	Kvartalsrapport 2022-Q2
2022-05-16	Ordinarie utdelning ONXEO 0.00 DKK
2022-05-12	Årsstämma 2022
2022-03-30	Bokslutskommuniké 2021
2021-09-14	Kvartalsrapport 2021-Q2
2021-05-14	Ordinarie utdelning ONXEO 0.00 DKK
2021-03-30	Bokslutskommuniké 2020
2020-09-17	Kvartalsrapport 2020-Q2
2020-06-01	Ordinarie utdelning ONXEO 0.00 DKK
2020-05-29	Årsstämma 2020
2020-04-17	Bokslutskommuniké 2019
2019-07-25	Kvartalsrapport 2019-Q2
2019-04-29	Ordinarie utdelning ONXEO 0.00 DKK
2019-04-26	Årsstämma 2019
2019-03-12	Bokslutskommuniké 2018
2018-10-25	Kvartalsrapport 2018-Q3
2018-07-27	Kvartalsrapport 2018-Q2
2018-05-17	Ordinarie utdelning ONXEO 0.00 DKK
2018-05-16	Årsstämma 2018
2018-05-04	Kvartalsrapport 2018-Q1
2018-03-29	Bokslutskommuniké 2017
2017-10-26	Kvartalsrapport 2017-Q3
2017-07-28	Kvartalsrapport 2017-Q2
2017-04-27	Ordinarie utdelning ONXEO 0.00 DKK
2017-04-26	Årsstämma 2017
2017-04-26	Kvartalsrapport 2017-Q1

Beskrivning

Land	Frankrike
Lista	First North Denmark
Sektor	Hälsovård
Industri	Bioteknik

Valerio Therapeutics är specialiserade inom bioteknik. Bolaget inriktar sig mot forskning och utveckling av läkemedel som används vid behandling av sällsynta onkologiska sjukdomar. Utöver huvudverksamheten används bolagets läkemedel vid behandling av cancer. Produkterna säljs under separata varumärken runtom den globala marknaden. Onxeo kom till vid en sammanslagning av BioAlliance Pharma och Topotarget och har sitt huvudkontor i Paris.

Filter

År

Typ

Språk

Rensa

2021-11-23 19:08:00 Onxeo Continues to Strengthen its Board of Directors 0,00%

2021-10-14 22:12:00 Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector +0,39%

2021-07-29 18:00:00 Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board -2,93%

2021-06-09 18:38:03 Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States +3,81%

2021-05-31 07:00:00 Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts -1,49%

2021-04-21 19:12:33 Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update -1,49%

2021-04-08 18:41:38 Onxeo to Present New Preclinical Data at AACR 2021 +3,75%

2020-11-09 18:00:00 Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results +2,00% | 6,52 MDKK

2020-10-22 18:00:00 Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors 0,00% | 1,20 MDKK

2020-10-21 19:30:00 Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan +0,40% | 0,74 MDKK

2020-09-17 18:29:17 Onxeo Reports its Financial Results for the First Half of 2020 and Provides an Update on its Activities +0,98% | 1,25 MDKK

2020-09-08 14:00:00 Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020 -3,38% | 1,09 MDKK

2020-09-03 18:00:00 Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States +4,72% | 7,06 MDKK

2020-08-27 18:38:34 Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer +7,92% | 14,8 MDKK

2020-07-29 18:30:00 Transfer of the Listing of Onxeo Securities From the Euronext Paris Regulated Market (Compartment C) to the Euronext Growth Paris Multilateral Trading Facility -1,96% | 2,68 MDKK

2020-06-22 13:00:00 New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020 +7,19% | 41,5 MDKK

2020-05-29 07:30:00 Onxeo Announces Approval of the REVocan Study by Regulatory Authorities +0,96% | 103 MDKK

2020-05-27 14:00:00 Bryan Garnier & Co Initiates Coverage of Onxeo with a “Buy” Recommendation +54,06% | 88,9 MDKK

2020-05-19 18:00:00 Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi +2,17% | 3,28 MDKK

2020-04-17 18:24:20 Onxeo Reports Full-Year 2019 Financial Results and Provides Business Update -7,76% | 2,09 MDKK

2020-04-06 18:30:00 Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC +2,72% | 7,07 MDKK

2020-02-27 17:45:00 Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020 -0,92% | 1,95 MDKK

2020-01-29 19:00:00 Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer +7,60% | 9,89 MDKK

2020-01-28 17:45:00 Onxeo to Present Next-Generation PARP Inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020 +2,27% | 1,55 MDKK

2020-01-20 21:19:00 Onxeo Publishes Shareholder Newsletter -0,33% | 0,97 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Valerio Therapeutics

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden